Europe Psychiatric and Nervous Drugs Market was valued at USD 25 Billion in 2022 and is projected to reach USD 36 Billion by 2030, growing at a CAGR of 5.3% from 2024 to 2030.
The Europe psychiatric and nervous drugs market has experienced significant growth over the past few years. This surge can be attributed to rising awareness of mental health issues and an increasing demand for better treatment options. From anti-depressants to anxiety-relieving drugs, the market serves a diverse range of psychiatric and neurological conditions, including depression, schizophrenia, anxiety disorders, and neurological diseases such as epilepsy and Parkinson's. The rise in demand is driven by a combination of evolving societal attitudes toward mental health and advancements in pharmaceutical research.
The pharmaceutical industry in Europe is rapidly developing innovative treatments to address a variety of conditions affecting the nervous system. As more people are diagnosed with mental health disorders, the need for targeted and effective treatments increases. This trend has created substantial opportunities for pharmaceutical companies to develop drugs tailored to individual needs. Moreover, regulatory bodies in Europe, such as the European Medicines Agency (EMA), have streamlined the approval processes for new psychiatric and nervous drugs, fueling growth within the market.
Industries ranging from healthcare providers to research laboratories are increasingly reliant on psychiatric and nervous drugs to meet the growing demand for mental health treatment. Hospitals, mental health clinics, and research institutions continue to be major consumers of these drugs, as they are essential in treating patients with psychiatric disorders. In addition, healthcare providers are exploring new ways to improve patient outcomes by integrating psychiatric drugs into personalized medicine regimens. This trend is expected to continue as patient-centric care becomes a focus across Europe.
As mental health becomes a priority across various sectors, the psychiatric and nervous drugs market in Europe is set to evolve, with a greater emphasis on innovation and access. Companies within this sector are also exploring solutions related to drug delivery systems, ensuring faster relief and better quality of life for individuals suffering from neurological and psychiatric disorders. While demand continues to rise, the sector remains heavily focused on the efficiency of treatments and patient adherence, which plays a key role in shaping future market trends.
Get an In-Depth Research Analysis of the Europe Psychiatric and Nervous Drugs Market Size And Forecast [2025-2032]
Â
Pfizer
Ely Lilly
Actavis
Mylan
Randox
Intellipharmaceutics
Astrazeneca
Lundbeck
Allergan
GSK
Otsuka Pharmaceutical
Takeda
NHU Group
Shionogi
APOTEX
Chengdu Kanghong Pharmaceutical
HUAHAI
Zhejiang Jianfeng
Beijing Winsunny Pharmaceutical
Â
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Europe Psychiatric and Nervous Drugs Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Europe Psychiatric and Nervous Drugs Market
Antidepressants
Antipsychotics
Anxiolytics
Stimulants
Mood Stabilizers
Hypnotics & Sedatives
Depression
Anxiety Disorders
Schizophrenia
Bipolar Disorder
Obsessive-Compulsive Disorder (OCD)
Attention-Deficit/Hyperactivity Disorder (ADHD)
Sleep Disorders
Oral
Injectable
Topical
Inhalation
Pediatric
Adult
Elderly
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
US (United States, US and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Psychiatric and Nervous Drugs Market Research Analysis
1. Introduction of the Europe Psychiatric and Nervous Drugs Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Europe Psychiatric and Nervous Drugs Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Europe Psychiatric and Nervous Drugs Market, By Type
6. Europe Psychiatric and Nervous Drugs Market, By Application
7. Europe Psychiatric and Nervous Drugs Market, By Geography
US
Europe
Asia Pacific
Rest of the World
8. Europe Psychiatric and Nervous Drugs Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Europe Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/